Featured Chrome Extensions:

Casey IRACs are produced by an AI that analyzes the opinion’s content to construct its analysis. While we strive for accuracy, the output may not be flawless. For a complete and precise understanding, please refer to the linked opinions above.

Keywords

appealpatent
appealpatentrespondent

Related Cases

Hunter Douglas, Inc. v. Harmonic Design, Inc., 153 F.3d 1318, 47 U.S.P.Q.2d 1769
View Case »
ResQNet.com, Inc. v. Lansa, Inc., 594 F.3d 860, 93 U.S.P.Q.2d 1553
View Case »
Jim Arnold Corp. v. Hydrotech Systems, Inc., 109 F.3d 1567, 42 U.S.P.Q.2d 1119
View Case »
Grant v. Raymond, 31 U.S. 218, 6 Pet. 218, 1832 WL 3447, 8 L.Ed. 376
View Case »
Enfish, LLC v. Microsoft Corp., 822 F.3d 1327, 118 U.S.P.Q.2d 1684
View Case »
Justia Law Link
LexisNexis Link
Westlaw Link
CourtListener Link
Oyez Link

Brenner v. Manson, 383 U.S. 519, 86 S.Ct. 1033, 16 L.Ed.2d 69, 148 U.S.P.Q. 689

Facts

In December 1957, Howard Ringold and George Rosenkranz applied for a patent on a novel process for making certain known steroids, claiming priority from a Mexican patent filed in December 1956. In January 1960, Manson, a chemist, filed an application for the same process, asserting he had discovered it first. The Patent Office denied Manson's application due to a lack of utility for the chemical compound produced. The Court of Customs and Patent Appeals reversed this decision, leading to the Supreme Court's review of the case.

In December 1957, Howard Ringold and George Rosenkranz applied for a patent on an allegedly novel process for making certain known steroids. They claimed priority as of December 17, 1956, the date on which they had filed for a Mexican patent. United States Patent No. 2,908,693 issued late in 1959. In January 1960, respondent Manson, a chemist engaged in steroid research, filed an application to patent precisely the same process described by Ringold and Rosenkranz.

Issue

Whether the practical utility of the compound produced by a chemical process is an essential element in establishing a prima facie case for the patentability of the process.

Whether the practical utility of the compound produced by a chemical process is an essential element in establishing a prima facie case for the patentability of the process.

Rule

Analysis

The Supreme Court analyzed the utility requirement in the context of Manson's claim, emphasizing that merely producing a known product does not satisfy the utility requirement unless the product is shown to be beneficial. The Court found that Manson's references to potential uses were insufficient to establish the utility of the process, as the Patent Office had determined that the compound's utility had not been adequately demonstrated.

Conclusion

The Supreme Court reversed the decision of the Court of Customs and Patent Appeals, affirming the Patent Office's determination that Manson's application did not meet the utility requirement for patentability.

The judgment of the CCPA is reversed.

Who won?

The prevailing party in this case was the Patent Office, as the Supreme Court reversed the decision of the Court of Customs and Patent Appeals. The Court upheld the Patent Office's determination that Manson's application for a patent did not satisfy the utility requirement, emphasizing that a mere assertion of potential usefulness is insufficient without concrete evidence of utility. The ruling reinforced the principle that patents should only be granted for inventions that provide a specific benefit to the public.

The judgment of the United States Court of Customs and Patent Appeals reversed.

You must be